Abbott (NYSE:ABT) agreed to pony up nearly $5.5 million to settle a class action lawsuit alleging a kickbacks scheme to push the use of its stent products, but admitted no wrongdoing in settling the case.
Abbott
Medtronic to invest $6M, create 150 jobs in Puerto Rico expansion
Diabetes: Abbott recalls blood glucose test strips
Abbott Diabetes Care (NYSE:ABT) said it issued a recall of its FreeStyle blood glucose test strips after reports of falsely low results.
Medicare considers coverage for Abbott’s MitraClip mitral valve repair system
Kardiametrics sues medical device makers over blood clot patents
FDA approves Abbott’s MitraClip heart device
Abbott beats The Street despite Q3 sales miss
Abbott (NYSE:ABT) shares ticked up today ahead of the market’s open after the healthcare giant beat Wall Street’s earnings expectations despite missing its 3rd-quarter sales target.
Abbott posted profits of $966 million, or 61¢ per share, on sales of $5.37 billion for the 3 months ended Sept. 30, for a 50.3% profit slide on sales growth of 2.0% compared with Q3 2012. Analysts had expected sales of $5.77 billion.
Federal Circuit denies re-hearing for Cordis patent claims against Medtronic, Abbott, Boston Scientific
A federal appeals court last week declined to revisit its decision to uphold the invalidation of patents covering drug-eluting stent technology.
Ireland finance chief denies Abbott, Boston Scientific paid little in taxes | MassDevice.com On Call
MASSDEVICE ON CALL — Irish finance minister Michael Noonan denied "emphatically" a recent report putting Boston Scientific’s (NYSE:BSX) and Abbott’s (NYSE:ABT) effective corporate tax rates in the country at 4% and 0%, respectively.